医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

AtriCure Announces Approval for the AtriClip in Japan

2016年01月20日 AM02:00
このエントリーをはてなブックマークに追加


 

WEST CHESTER, Ohio

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for its AtriClip™ products, which includes the AtriClip™ Standard and the AtriClip Pro™ devices.

“We are excited to bring the AtriClip to Japan,” said Mike Carrel, President and CEO of AtriCure. “This is an important milestone for our growth prospects in the Japanese market, and we are thrilled that we can offer our LAA products to Japanese customers and patients. We see a great opportunity in the Japanese market for this solution, and are looking forward to the launch.”

The company’s distributor in Japan, Century Medical Inc. (CMI), worked closely with the company to secure approval. In addition, CMI will be working closely with the MHLW to secure healthcare insurance system reimbursement for the AtriClip products. CMI is the company’s exclusive distributor in Japan under an agreement that runs through 2019.

“We’re pleased to have secured this important approval. We expect that with this leading technology we will be able to significantly help Japanese patients in the area of LAA occlusion,” said Takahiko Motani, president and CEO of CMI.

The approval marks the first time that these products will be available in the Japanese market. The AtriClip is the fastest growing part of the AtriCure product portfolio. Through the nine months ending September 30, 2015, sales of the AtriClip grew at a rate of 48% on a global basis as compared to the prior period in 2014.

About AtriCure

AtriCure, Inc. is a medical device company providing innovative atrial fibrillation (Afib) solutions designed to produce superior outcomes that reduce the economic and social burden of atrial fibrillation. AtriCure’s Synergy™ Ablation System is the first and only surgical device approved for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. AtriCure’s AtriClip™ left atrial appendage management (LAAM) exclusion device is the most widely sold device worldwide that’s indicated for the occlusion of the left atrial appendage. The company believes cardiothoracic surgeons are adopting its ablation and LAAM devices for the treatment of Afib and reduction of Afib related complications such as stroke. AtriCure recently acquired nContact, a leader in minimally invasive technology for epicardial ablation. nContact’s mission is to transform the underserved arrhythmia population through a multidisciplinary epicardial-endocardial ablation approach. Afib affects more than 33 million people worldwide. For more information visit AtriCure.com or follow us on Twitter @AtriCure.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160119006351/en/

CONTACT

AtriCure, Inc.
Media Relations
Valerie Storch-Willhaus,
612-605-3311
Director, Corporate Marketing and Communications
vstorch-willhaus@atricure.com
or
Investor
Relations
Andy Wade, 513-755-4564
Senior Vice President and
Chief Financial Officer
awade@AtriCure.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 三井化学开发全球首款灵活的高强度柔性无纺布AIRYFA™
  • APR应用制药研究公司参加第9届ChinaBio®合作论坛:依托瑞士创新产品和科学技术深耕中国市场
  • Dompé用于治疗中度或重度神经营养性角膜炎成人患者的Oxervate®(Cenegermin滴眼液)获得欧盟CHMP肯定意见
  • SCIEX Sponsored Award Recognizes Notable Contributions to Electrodriven Separations
  • LMDのV-Sensorがインドでバイタルサインを測定